Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACTS<br />
General and Media Contact<br />
Emmanuelle Delabre<br />
Business Development<br />
Aram Mangasarian, PhD<br />
Chief Business Officer<br />
ADDRESS<br />
NOXXON Pharma AG<br />
Max-Dohrn-Strasse 8-10<br />
10589 Berlin<br />
Germany<br />
TELEPHONE<br />
+49 30 726 247 0<br />
Emmanuelle Delabre<br />
+49 30 726 247 100<br />
FAX<br />
+49 30 726 247 225<br />
EMAIL<br />
Noxxon@noxxon.com<br />
ibuchanan@noxxon.com<br />
edelabre@noxxon.com<br />
amangasarian@noxxon.com<br />
YEAR FOUNDED<br />
1997<br />
NOXXON Pharma AS<br />
www.noxxon.com<br />
FINANCIAL SUMMARY<br />
Since 2007 NOXXON has closed two financing rounds and raised approximately €72m Euros from venture<br />
capital investors. NOXXON’s major investors include Sofinnova Partners, TVM Capital, DEWB, Edmond de<br />
Rothschild Investment Partners, NGN Capital, Seventure, IBB Beteiligungsgesellschaft, Dow and GoodVent.<br />
COMPANY PROFILE<br />
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary<br />
therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies.<br />
NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics:<br />
NOX-E36 is an anti-CCL2 (MCP-1) Spiegelmer® currently in a Phase IIa study in diabetics with albuminuria.<br />
CCL2 is involved in recruitment of immune cells to the kidney in diabetic patients, a process which is associated<br />
with progression of chronic kidney disease.<br />
NOX-A12 is an anti-CXCL12 (SDF-1) Spiegelmer® that has begun two Phase IIa studies in hematological<br />
oncology indications (chronic lymphocytic leukemia and multiple myeloma). CXCL12 acts via its two receptors,<br />
CXCR4 and CXCR7, to mediate tumor invasion, metastasis and resistance to chemotherapy.<br />
NOX-H94 is an anti-hepcidin Spiegelmer® currently completing Phase I safety studies as well as a Phase I<br />
human pharmacodynamic study to assess its ability to prevent inflammation-induced hypoferremia. Hepcidin<br />
is the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease via its<br />
interaction with the iron export protein, ferroportin.<br />
The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have<br />
generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a<br />
well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees<br />
and a highly experienced management team<br />
MANAGEMENT<br />
Senior Management<br />
Iain Buchanan, Chief Executive Officer<br />
Dr Matthias Baumann, Chief Medical Officer<br />
Dr Sven Klussmann, Chief Scientific Officer<br />
Aram Mangasarian, PhD, Chief Business Officer<br />
Supervisory Board<br />
Dr Walter Wenninger, Chairman of the Supervisory Board<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS